PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15084142-6	2004	Single doses of beta(2)-adrenoceptor agonists significantly increase heart rate and decrease potassium concentrations compared with placebo.	Potassium	93-102	adrenoceptor beta 2	Homo sapiens	16-36	
16363886-20	2005	Regular review of cardiovascular status (and monitoring of serum potassium concentration) in patients taking beta(2)-adrenoceptor agonists is crucial.	Potassium	65-74	adrenoceptor beta 2	Homo sapiens	109-129	
15084142-7	2004	CONCLUSIONS: Initiation of beta(2)-adrenoceptor agonist treatment increases heart rate and decreases potassium concentrations, while continued use may increase the risk of adverse cardiovascular events.	Potassium	101-110	adrenoceptor beta 2	Homo sapiens	27-47	
2178376-6	1990	Although diuretic use is the most frequent cause of hypokalemia, epinephrine can also lower serum potassium as a result of stimulation of the beta 2 adrenoreceptor.	Potassium	98-107	adrenoceptor beta 2	Homo sapiens	142-163	
8866625-0	1996	Effect of beta 2-adrenoceptor agonists on plasma potassium and cardiopulmonary responses on exercise in patients with chronic obstructive pulmonary disease.	Potassium	49-58	adrenoceptor beta 2	Homo sapiens	10-29	
1928061-9	1991	However, it is important to appreciate that the response to beta 2-adrenoreceptor-mediated internal potassium disposal is heterogeneous as judged by the variable responses to epinephrine infusion.	Potassium	100-109	adrenoceptor beta 2	Homo sapiens	60-81	
9440565-6	1998	RESULTS: There was significant (p < 0.05) subsensitivity of systemic beta2-AR responses (as AUC) following FM + PL: for heart rate (before vs after), 760 vs 340 beats (95% confidence interval [CI], 160 to 680), for tremor 0.39 vs 0.19 log units/h (95% CI, 0.01 to 0.41), and for potassium, -0.34 vs -0.19 mmol x h/L (95% CI, -0.04 to -0.28).	Potassium	282-291	adrenoceptor beta 2	Homo sapiens	72-80	
8847943-4	1995	Ritodrine and salbutamol significantly increased plasma cyclic AMP and decreased serum potassium concentrations indicating the presence of beta 2-adrenoceptor stimulation.	Potassium	87-96	adrenoceptor beta 2	Homo sapiens	139-158	
1681847-0	1991	Effects of selective beta 2-adrenoceptor blockade on serum potassium and exercise performance in normal men.	Potassium	59-68	adrenoceptor beta 2	Homo sapiens	21-40	
2821083-0	1987	Impairment of beta 2-adrenoceptor-stimulated potassium uptake in end-stage renal disease.	Potassium	45-54	adrenoceptor beta 2	Homo sapiens	14-33	
2821083-5	1987	Furthermore, the final plasma potassium concentration slightly exceeded baseline in the patients but was significantly reduced in controls, leading to the conclusion that an abnormal responsiveness of the beta 2 adrenoceptor may contribute to the impaired potassium tolerance found in patients who have end-stage renal disease.	Potassium	30-39	adrenoceptor beta 2	Homo sapiens	205-224	
2821083-5	1987	Furthermore, the final plasma potassium concentration slightly exceeded baseline in the patients but was significantly reduced in controls, leading to the conclusion that an abnormal responsiveness of the beta 2 adrenoceptor may contribute to the impaired potassium tolerance found in patients who have end-stage renal disease.	Potassium	256-265	adrenoceptor beta 2	Homo sapiens	205-224	
2427869-7	1986	The beta 2-adrenoceptor-mediated increases in plasma cyclic AMP and decreases in plasma potassium were similar in the BHT and control groups.	Potassium	88-97	adrenoceptor beta 2	Homo sapiens	4-23